Akebia Therapeutics Announces Poster Presentations at National Kidney Foundation Spring Clinical Meetings 2023

Rhea-AI Summary

Akebia Therapeutics, Inc. (Nasdaq: AKBA) announced its participation in the National Kidney Foundation (NKF) Spring Clinical Meetings 2023, taking place from April 11 to April 15 in Austin, Texas. During this event, Akebia will present posters focusing on critical research related to kidney disease, highlighting topics such as inpatient admission and mortality rates among Medicare patients with dialysis-dependent chronic kidney disease (CKD) and blood transfusion rates. The company aims to enhance the lives of individuals affected by kidney disease and is committed to showcasing its findings at this prominent clinical forum. Attendees can visit Akebia's booth (#801) to learn more about their initiatives and research findings.

Positive

• Participation in a key industry event enhances visibility among stakeholders.
• Presentation of research may strengthen credibility in the kidney disease sector.

Negative

• None.

CAMBRIDGE, Mass., April 7, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present posters at the National Kidney Foundation (NKF) Spring Clinical Meetings 2023 (SCM23), which will take place on demand and live in Austin, Texas on April 11 – 15, 2023.   

Abstracts are available online in the SCM22 Abstract and ePoster Gallery.

Akebia posters include:

• Inpatient Admission and Mortality Rates Among Medicare Patients With Dialysis-Dependent CKD and Hyporesponse to ESAs (Poster #179)
• Blood Transfusion and Transplant Rates Among Medicare Patients With Dialysis-Dependent CKD and Hyporesponse to ESAs (Poster #180)

NKF SCM23 attendees can visit the Akebia booth (#801) in the Exhibit Hall.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics® is a registered trademark of Akebia Therapeutics, Inc.

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-announces-poster-presentations-at-national-kidney-foundation-spring-clinical-meetings-2023-301792282.html

SOURCE Akebia Therapeutics

FAQ

What is Akebia Therapeutics presenting at the NKF Spring Clinical Meetings 2023?

Akebia is presenting posters on inpatient admission and mortality rates, as well as blood transfusion and transplant rates among Medicare patients with dialysis-dependent CKD.

When are the NKF Spring Clinical Meetings 2023 taking place?

The NKF Spring Clinical Meetings 2023 will be held from April 11 to April 15, 2023.

Where is Akebia's booth located at the NKF Spring Clinical Meetings?

Akebia's booth is located at #801 in the Exhibit Hall.

What is the significance of Akebia's presentations at the NKF event?

The presentations are significant as they highlight important research findings that could impact treatment and care in kidney disease.